{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T02:40:45Z","timestamp":1787971245817,"version":"build-2784847793"},"reference-count":5,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"am","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["1K23AR078930"],"award-info":[{"award-number":["1K23AR078930"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.jaad.2023.02.028","type":"journal-article","created":{"date-parts":[[2023,2,24]],"date-time":"2023-02-24T22:25:17Z","timestamp":1677277517000},"page":"1396-1397","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Spironolactone use for acne is not associated with an increased risk of venous thromboembolism: A matched, retrospective cohort study"],"prefix":"10.1016","volume":"88","author":[{"given":"Ali","family":"Shields","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelsey","family":"Flood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John S.","family":"Barbieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2023.02.028_bib1","doi-asserted-by":"crossref","first-page":"d2151","DOI":"10.1136\/bmj.d2151","article-title":"Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case-control study using United States claims data","volume":"342","author":"Jick","year":"2011","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.jaad.2023.02.028_bib3","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.jaad.2020.07.075","article-title":"Validating the optimal classification approach using International Classification of Diseases, 10th Revision codes to identify dermatology patients with acne","volume":"84","author":"Barbieri","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2023.02.028_bib2","series-title":"Combined Hormonal Contraceptives (CHCs) and the Risk of Cardiovascular Disease Endpoints","year":"2011"},{"issue":"5","key":"10.1016\/j.jaad.2023.02.028_bib4","first-page":"287","article-title":"Risk of venous thromboembolism with use of combined oral contraceptives","volume":"91","author":"Saguil","year":"2015","journal-title":"Am Fam Physician"},{"issue":"7","key":"10.1016\/j.jaad.2023.02.028_bib5","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1001\/jamadermatol.2021.1570","article-title":"Incidence of venous thromboembolism in patients with dermatologist-diagnosed chronic inflammatory skin diseases","volume":"157","author":"Schneeweiss","year":"2021","journal-title":"JAMA Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962223002815?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962223002815?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T23:23:40Z","timestamp":1759274620000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962223002815"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":5,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S0190962223002815"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2023.02.028","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Spironolactone use for acne is not associated with an increased risk of venous thromboembolism: A matched, retrospective cohort study","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2023.02.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}